Copper-64 Theragnostic Dosing With PET/CT Eligibility Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current theragnostic approaches for using Copper-64 (64CuCl2) in cancer treatment lack clear dosage regimens and formulations, leading to ineffective and unsafe treatments due to unpredictable biodistribution and lack of monitoring, especially for common cancers like breast, prostate, and brain tumors.
Innovation Solution
A theragnostic method using Copper-64 (64CuCl2) with a radioconcentration of 925 MBq/mL or higher, administered intravenously, combined with PET/CT imaging to predict biodistribution and monitor treatment response, ensuring safe and effective therapeutic doses for neoplasms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple separate tests (tumor biopsy, blood tests, imaging) are performed to assess cancer patients, then comprehensive cancer assessment is achieved, but test complexity and cost increase
Solution Approach 1:
The patent combines multiple separate cancer assessment tests (tumor biopsy, blood tests, imaging) into a single integrated liquid biopsy test. This consolidation maintains comprehensive cancer assessment capability while reducing test complexity and cost by performing all analyses in one unified test procedure.
Solution Approach 2:
The liquid biopsy test is designed to perform multiple functions simultaneously: detecting cancer presence, determining cancer type, identifying molecular markers, and assessing treatment response. This multi-functionality eliminates the need for multiple separate specialized tests, resolving the contradiction between comprehensive assessment and test complexity.
2Reliability
If traditional cancer tests are used, then cancer detection is achieved, but treatment personalization is limited
Solution Approach 1:
The test analyzes multiple molecular parameters simultaneously including gene mutations, protein markers, and genetic markers in the liquid biopsy sample. By changing from single-parameter detection to multi-parameter analysis, the test maintains high cancer detection accuracy while enabling treatment personalization through identification of specific molecular targets.
Solution Approach 2:
The test provides feedback information about molecular markers and genetic characteristics that guide treatment selection. This feedback mechanism enables doctors to personalize treatment plans based on the patient's specific molecular profile, resolving the contradiction between reliable detection and treatment adaptability.
3Adaptability or versatility
If comprehensive molecular analysis is performed, then treatment personalization is improved, but test cost increases
Solution Approach 1:
By merging multiple molecular analysis procedures into a single liquid biopsy test, the patent reduces overall test cost while maintaining comprehensive molecular analysis capability. The combined test performs gene mutation analysis, protein marker detection, and genetic marker identification in one procedure, eliminating redundant costs associated with separate tests.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A radiopharmaceutical composition is here described comprising as the active ingredient copper- 64 in ionic form (64Cu++), in combination with suitable excipients, and/or diluents, having radioconcentration comprised between 50 and 3,500 MBq/mL at calibration time. Such radiopharmaceutical composition is useful in a method for treating a subject affected by a neoplasia. Such method may comprise a step for evaluating the eligibility of a patient for the treatment, in which 64Cu++ cellular uptake is detected. In case no uptake is detectable, the treatment is not advisable. In case radioactive copper uptake from cancer lesions is detectable, this has a predictive value of response to treatment and the subject is selected for the treatment. If the patient is eligible for the treatment and is selected for the treatment, the method further comprises a step of treating cancer in said subject by administering a therapeutically effective amount of the same 64Cu++ salt.